Hatch-Waxman Improvement Act of 2022
This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of one another).
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2022-06-13 | IntroReferral | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. | Senate |
| 2022-06-13 | IntroReferral | Introduced in Senate | Library of Congress |